Related Experiment Video

Updated: Jul 10, 2026

Magnetic Resonance Imaging of Multiple Sclerosis at 7.0 Tesla
08:51

Magnetic Resonance Imaging of Multiple Sclerosis at 7.0 Tesla

Published on: February 19, 2021

[Innovations on multiple sclerosis]

Y Mikaeloff1, H Maurey, M Tardieu

  • 1Service de neurologie pédiatrique et centre de référence sur les maladies inflammatoires du cerveau, Assistance publique-Hôpitaux de Paris, hôpital Bicêtre, Le Kremlin-Bicêtre cedex, France.

Archives De Pediatrie : Organe Officiel De La Societe Francaise De Pediatrie
|November 6, 2007
PubMed

Insights

Pediatric Multiple Sclerosis (MS) understanding has improved with a 7-year French cohort study. Early diagnosis and careful cognitive evaluation are crucial for children with MS.

Area of Science:

  • Neurology
  • Epidemiology
  • Pediatrics

Context:

  • Epidemiological studies, including a 7-year French cohort of nearly 500 children, have enhanced understanding of pediatric Multiple Sclerosis (MS).
  • Pediatric MS can manifest as early as age 2, with distinct symptoms compared to adolescent onset.
  • The progression to motor disability in children is slower than in adults, necessitating careful evaluation of cognitive impairment.

Purpose:

  • To summarize current understanding of pediatric Multiple Sclerosis based on recent epidemiological data.
  • To highlight key differences in symptom presentation and disease progression in pediatric MS.
  • To inform clinical management regarding treatment options and risk factors.

Summary:

  • A French cohort study followed almost 500 children with MS for over 7 years.
  • Symptoms vary by age, with cognitive impairment being a significant concern.
  • Interferon beta treatment is viable for children under 10, and environmental factors like EBV infection and passive smoking may increase risk.

Impact:

  • Improved diagnostic and management strategies for pediatric MS.
  • Increased awareness of cognitive involvement in pediatric MS.
  • Guidance on early treatment initiation and identification of environmental risk factors.

More Related Videos

Two-photon Imaging of Cellular Dynamics in the Mouse Spinal Cord10:44

Two-photon Imaging of Cellular Dynamics in the Mouse Spinal Cord

Published on: February 22, 2015

Induction and Diverse Assessment Indicators of Experimental Autoimmune Encephalomyelitis06:19

Induction and Diverse Assessment Indicators of Experimental Autoimmune Encephalomyelitis

Published on: September 9, 2022

Related Concept Videos

Multiple Sclerosis l: Introduction01:19

Multiple Sclerosis l: Introduction

Multiple sclerosis is a chronic autoimmune disease of the central nervous system (CNS) that affects the brain, spinal cord, and optic nerves. It is an inflammatory demyelinating disorder and a leading cause of neurological disability in young adults.EpidemiologyMS commonly begins between 20 and 40 years of age and is twice as common in women. Its exact cause remains unclear, but genetic susceptibility contributes, with higher risk in first-degree relatives and identical twins. A greater...
Parkinson's Disease: Treatment01:24

Parkinson's Disease: Treatment

Neurodegenerative disorders, such as Parkinson's Disease (PD), involve the gradual and irreversible destruction of neurons in particular brain areas. These disorders exhibit standard features like proteinopathies, selective vulnerability of some neurons, and an interaction of intrinsic properties, genetics, and environmental influences in neural injury.
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of its...
Diabetic Neuropathy01:22

Diabetic Neuropathy

DefinitionDiabetic neuropathy is nerve damage caused by long-standing diabetes mellitus. It results directly from prolonged high blood sugar levels.PathophysiologyThe pathophysiology of diabetic neuropathy involves both metabolic and vascular disturbances triggered by chronic hyperglycemia.Metabolic injury: Elevated glucose levels activate the polyol pathway within nerve cells, leading to the accumulation of sorbitol and fructose. This increases oxidative stress, disrupts normal nerve...
Inflammatory Bowel Disease IV: Pharmacological Management01:29

Inflammatory Bowel Disease IV: Pharmacological Management

Upon diagnosis, managing Inflammatory Bowel Disease (IBD) involves addressing several crucial aspects. The primary goals include resting the bowel, correcting malnutrition, and providing symptomatic relief. Resting the bowel may consist of medications to reduce inflammation and promote healing. Correcting malnutrition is essential, often requiring dietary adjustments and nutritional supplements. Symptomatic relief aims to ease pain, diarrhea, and other discomforts in IBD.
Pharmacologic...
Alzheimer's Disease: Treatment01:22

Alzheimer's Disease: Treatment

Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...